AstraZeneca joins Pfizer in a landmark agreement with the Trump administration, promising "most-favored nation" drug prices, direct-to-consumer sales up to 80% off list price, and a massive investment in U.S. manufacturing in exchange for a three-year tariff exemption.
The Trump administration is working on "TrumpRx," a new site connecting consumers to drugmakers, pharmacies, and discount programs like GoodRx to help lower prescription costs.
Pfizer avoided US tariffs by offering big drug discounts (TrumpRx). This deal is a blueprint. European drug stocks (AstraZeneca, Roche) surged hoping for similar agreements to protect their crucial sales from Trump's 100% import tax threat.
Pfizer becomes the first pharmaceutical company to announce a drug-pricing deal with the Trump administration, promising lower prices for up to 100 million patients and committing $70 billion to domestic R&D and manufacturing.
Pfizer is buying Metsera for $4.9 billion to gain promising new obesity drugs. The portfolio includes four clinical treatments, like once-a-month shots and future oral pills, aiming for better efficacy and easier patient use to fight the growing obesity epidemic.
New COVID vaccines from Moderna & Pfizer show strong protection against the dominant LP.8.1 variant. Moderna's Spikevax (for high-risk 6mo-64yrs & all 65+) boosted antibodies 8x. Pfizer's also effective. No new safety issues found.
